Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Rivaroxaban use following bariatric surgery

  • 914 Accesses

  • 3 Citations

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Mahlmann A, Gehrisch S, Beyer-Westendorf J (2013) Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. J Thromb Thrombolysis 36:533–535

  2. 2.

    Stampfuss J, Kubitza D, Becka M, Mueck W (2013) The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther 51:549–561

  3. 3.

    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59–7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46:549–558

  4. 4.

    Xarelto Prescribing Information (2013). http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf. Accessed 17 Dec 2013

  5. 5.

    Protocol for: Patel MR, Mahaffey KW, Garg J, et al. (2013) Rivaroxaban versus warfarin in nonvalvular atrial abrillation. N Engl J Med 2011; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1009638/suppl_file/nejmoa1009638_protocol.pdf. Accessed 17 Dec 2013

  6. 6.

    Protocol for: The EINSTEIN–PE investigators (2013). Oral rivaroxaban for the treatment of symptomatic pulmonary. N Engl J Med 2012; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1113572/suppl_file/nejmoa1113572_protocol.pdf. Accessed 17 Dec 2013

  7. 7.

    Protocol for: The EINSTEIN investigators (2013). Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; http://www.nejm.org/doi/suppl/10.1056/NEJMoa1007903/suppl_file/nejmoa1007903_protocol.pdf. Accessed 17 Dec 2013

  8. 8.

    Centers for Disease Control and Prevention (2013). National Health and Nutrition Examination Survey. Intake of calories and selected nutrients for the United States Population, 1999–2000. http://www.cdc.gov/nchs/data/nhanes/databriefs/calories.pdf. Accessed 17 Dec 2013

  9. 9.

    Finks JF, English WJ, Carlin AM, Krause KR, Share DA, Banerjee M, Birkmeyer JD, Birkmeyer NJ (2012) Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative. Ann Surg 255:1100–1104

  10. 10.

    Magnani JW, Hylek EM, Apovian CM (2013) Obesity begets atrial fibrillation: a contemporary summary. Circulation 128:401–405

  11. 11.

    Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2007) Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59–7939) in healthy subjects. J Clin Pharmacol 47:218–226

  12. 12.

    University of California San Francisco (2013). Dietary guidelines after bariatric surgery. http://www.ucsfhealth.org/education/dietary_guidelines_after_gastric_bypass/. Accessed 17 Dec 2013

  13. 13.

    Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA (1997) Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 157:2562–2568

  14. 14.

    Smith SB, Geske JB, Maguire JM, Zane NA, Carter RE, Morgenthaler TI (2010) Early anticoagulation is associated with reduced mortality for acute pulmonary embolism. Chest 137:1382–1390

  15. 15.

    Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546

Download references

Conflict of interest

Drs. Bareket and Thomas report receiving consulting fees from Janssen Pharmaceuticals, the manufacturer of rivaroxaban.

Author information

Correspondence to Zachariah Thomas.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thomas, Z., Bareket, Y. & Bennett, W. Rivaroxaban use following bariatric surgery. J Thromb Thrombolysis 38, 90–91 (2014). https://doi.org/10.1007/s11239-014-1057-6

Download citation

Keywords

  • Atrial Fibrillation
  • Gastric Bypass
  • Caloric Intake
  • Venous Thromboembolism
  • Rivaroxaban